http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2017512474-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-554 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-706 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7068 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7064 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-167 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-192 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate | 2015-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2017-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2017512474-A |
| titleOfInvention | Methods for predicting tumor response to DNA methylation inhibitors and alternative treatment regimens to overcome resistance |
| abstract | The present invention provides a method for predicting the susceptibility of patients suffering from cancer diseases to DNA methylation inhibitor therapy. The method comprises (1) the level of expression of a bromodomain-containing gene, and / or (2) the level of expression of other genes listed in the specification, and / or (3) the expression of a bromodomain-containing protein. Mutations with non-synonymous changes in amino acid sequence of levels, bromodomain-containing genes, and / or (4) mutations with non-synonymous changes in amino acid sequences of expression of other genes listed in the specification, and / or Or (5) a half-inhibitory concentration (IC50) of an inhibitor of DNA methyltransferase, histone acetyltransferase, histone deacetylase, and / or histone demethylase is determined in vitro in cancer cells taken from the patient And compare to the value for the parental species of the cell It encompasses. Here, the increase in (IC50) represents cross resistance and / or the half-inhibitory concentration (IC50) of a selective BET bromodomain inhibitor, and the decrease in (IC50) represents sensitivity. The present invention further provides combination therapy for cancer using bromodomain inhibitors in combination with DNA methylation inhibitors. |
| priorityDate | 2014-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 298.